Business & Economics
Trump Orders 100 % Tariff Threat on Patented Drug Imports and Resets Metal Duties
On 2 April 2026, President Trump invoked Section 232 to impose a tariff ladder that rises to 100 % on patented drug imports from companies without U.S. price-cut/onshoring deals and re-defined his existing 50 % metal tariffs to capture the full customs value of products.
Focusing Facts
- Tariff clock: large drugmakers face the new levy after 120 days (July 31), smaller firms after 180 days (Sept 29).
- Imports from the EU, Japan, South Korea, and Switzerland are capped at 15 %, while the U.K. receives a 10 % rate that can fall to zero under a future trade pact.
- Metal-containing goods whose steel/aluminum/copper content exceeds 15 % of weight now incur a flat 25 % tariff on the entire item; below that threshold, only country-specific duties apply.
Context
Washington’s turn toward punitive pharma tariffs echoes Richard Nixon’s 10 % across-the-board surcharge in 1971 and, further back, the Smoot-Hawley duties of 1930—both framed as emergency maneuvers to protect U.S. industry yet ultimately spurring retaliation and supply-chain shifts. Trump’s latest move, pivoting from the global “Liberation Day” tariffs struck down by the Supreme Court in February, exemplifies a longer arc in which presidents stretch national-security statutes (from Eisenhower’s 1958 oil quotas to Trump’s 2018 steel tariffs) to manage economic policy unilaterally. By singling out patented drugs—an industry that once seemed tariff-proof—Washington signals that the same de-risking logic applied to semiconductors now extends to health-care supply chains. Whether this cements a 21st-century mercantilist regime or fades like past surcharges will shape manufacturing geography, R&D incentives, and allied trade relations for decades; on a century scale, it marks another ratchet in the steady politicization of global commerce rather than an isolated outburst.
Perspectives
U.S. business-oriented outlets
e.g., U.S. News & World Report, ArcaMax, Inc. — Present the executive order chiefly as a disruptive pressure tactic that could hike drug prices and rattle supply chains, quoting PhRMA and BIO warnings that tariffs may "jeopardize billions in U.S. investments." Heavy reliance on pharmaceutical trade-group voices foregrounds corporate cost concerns while giving scant attention to the administration’s claim that patients will ultimately pay less.
Left-leaning international media
e.g., The Guardian, The Independent, Free Malaysia Today — Frame the move as another example of Trump’s populist protectionism, stressing that similar tariffs were struck down by the Supreme Court and arguing the policy is unlikely to revive U.S. industry or lower prices. By spotlighting court defeats and critics’ surveys but omitting recent company onshoring deals, the coverage tilts toward an anti-Trump narrative and downplays any potential economic upside.
Indian and development-focused outlets
e.g., Asian News International, Devdiscourse — Describe the tariffs as a calculated U.S. bid to reduce foreign dependence while noting that Indian generics remain exempt for now, signalling firms have time to strike reshoring deals. The emphasis on exemptions and future negotiation windows reassures domestic readers yet glosses over the longer-term threat that duties could expand to the generics sector, as officials openly caution. ( Asian News International (ANI) , Devdiscourse )
Like what you're reading?